[Efficacy and prognostic analysis of frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone regimens (VR-CAP) for patients with mantle cell lymphoma]

Zhonghua Xue Ye Xue Za Zhi. 2021 May 14;42(5):415-419. doi: 10.3760/cma.j.issn.0253-2727.2021.05.011.

[Article in Chinese]

Authors

Y W Cao¹, Z Zheng¹, P P Xu¹, S Cheng¹, L Wang¹, Y Qian¹, W L Zhao¹

Affiliation

¹ Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

PMID: 34218585
PMCID: PMC8293007
DOI: 10.3760/cma.j.issn.0253-2727.2021.05.011

No abstract available

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bortezomib / therapeutic use
Cyclophosphamide / therapeutic use
Doxorubicin / therapeutic use
Humans
Lymphoma, Mantle-Cell* / drug therapy
Prednisone / therapeutic use
Prognosis
Rituximab / therapeutic use
Vincristine / therapeutic use

Substances

Rituximab
Vincristine
Bortezomib
Doxorubicin
Cyclophosphamide
Prednisone

Grants and funding

基金项目：国家自然科学基金（81520108003、81830007、81670176）；上海市科委课题（14430723400、14140903100、16JC1405800）；上海市杰出青年医学人才培养计划；上海市教委高原高峰计划（20152206、20152208）